ESC 2020 | Revascularization Strategies: Ventricular Dysfunction Might Tilt the Scales

Patients included in the ISCHEMIA trial who had a history of cardiac failure or ventricular function deterioration will benefit from revascularization vs. optimal medical treatment. This is a pre-specified analysis of the paradigmatic ISCHEMIA trial.

ESC 2020 | La disfunción ventricular puede inclinar la balanza para decidir la revascularización

The ISCHEMIA was published in March 2020 in NEJM and went somewhat unnoticed due to the COVID-19 pandemic. 

At the time, the ISCHEMIA-CKD also came out; it looked at a population of higher baseline risk (patients with chronic kidney disease) and also failed to show revascularization benefits. 

Now, from the ESC 2020, we receive information on another high risk subgroup: patients with cardiac failure or ventricular function deterioration. 

These findings suggest that stable patients with moderate to severe ischemia and evidence of mild ventricular function deterioration will benefit from a more invasive therapy such as revascularization (be it percutaneous or surgical). 


Read also: Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM.


According to Dr. Renato Lopes, presenter and main author of this study, these results only generate hypothesis given the small number of patients with ventricular function deterioration included in the study. 

Of the 5129 patients included in the ISCHEMIA, only 4% had a history of cardiac failure and only 1.1% had required hospitalization because of it. Mean ventricular function of the global population was 60% vs 44% of this small subgroup of higher risk.

The combined end point occurred in 17.2% of patients undergoing revascularization vs. 29.3% of patients receiving the conservative therapy (p=0.055).


Read also: AHA 2019 | ISCHEMIA: The Invasive Approach (PCI or Surgery) Results Similar to Optimal Medical Treatment.


Revascularization type was split between PCI and CABG, depending on immediate risk and protection against future events at long term. 

These outcomes are on the same line of the STITCHES outcomes and call for further research. 

Original Title: Initial invasive versus conservative management for stable ischemic heart disease with a history of heart failure or left ventricular dysfunction: insights from the ISCHEMIA trial.

Reference: Lopes R, et al. Presentado en forma virtual en el congreso ESC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...